{"id":46877,"date":"2026-04-10T07:29:22","date_gmt":"2026-04-10T07:29:22","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/46877\/"},"modified":"2026-04-10T07:29:22","modified_gmt":"2026-04-10T07:29:22","slug":"novartis-sells-11-billion-bonds-to-fund-avidity-acquisition-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/46877\/","title":{"rendered":"Novartis Sells $11 Billion Bonds to Fund Avidity Acquisition"},"content":{"rendered":"<p class=\"ArticleBodyText_articleBodyContent__17wqE typography_articleBody___5jDr\" data-component=\"paragraph\"><a href=\"https:\/\/www.bloomberg.com\/quote\/NOVN:SW\" target=\"_blank\" rel=\"noopener nofollow\" class=\"media-ui-Link_link-tVkXhPLPofs-\" data-component=\"link\">Novartis AG<\/a> raised $11 billion to help fund its <a href=\"https:\/\/www.bloomberg.com\/news\/articles\/2025-10-26\/novartis-agrees-to-buy-avidity-biosciences-for-72-per-share\" target=\"_blank\" rel=\"noopener nofollow\" class=\"media-ui-Link_link-tVkXhPLPofs-\" data-component=\"link\">purchase<\/a> of Avidity Biosciences Inc., adding to a flurry of buyout-related bond sales. <\/p>\n<p class=\"ArticleBodyText_articleBodyContent__17wqE typography_articleBody___5jDr\" data-component=\"paragraph\">A unit of the Swiss drugmaker sold investment-grade US dollar <a href=\"https:\/\/www.bloomberg.com\/news\/terminal\/TC0CU2GENSW0\" class=\"media-ui-Link_link-tVkXhPLPofs- whitespace-normal\" target=\"_blank\" rel=\"noopener nofollow\" data-component=\"link\">bondsBloomberg Terminal<\/a> in seven tranches, with maturities ranging from three to 30 years, according to a person familiar with the matter. A five-year floating-rate note was dropped during syndication, added the person, who asked not to be identified as they\u2019re not authorized to speak publicly.<\/p>\n","protected":false},"excerpt":{"rendered":"Novartis AG raised $11 billion to help fund its purchase of Avidity Biosciences Inc., adding to a flurry&hellip;\n","protected":false},"author":2,"featured_media":46878,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[127],"tags":[11550,27147,27149,13692,4397,27150,27148,231,239,206,13223,2561],"class_list":{"0":"post-46877","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novartis","8":"tag-abbott-laboratories","9":"tag-atrium-therapeutics-inc","10":"tag-baker-hughes-co","11":"tag-bonds","12":"tag-drugs","13":"tag-eaton-corp-plc","14":"tag-keurig-dr-pepper-inc","15":"tag-markets","16":"tag-middle-east","17":"tag-novartis","18":"tag-novartis-ag-reg","19":"tag-us-dollar-spot"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116379239217159154","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/46877","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=46877"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/46877\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/46878"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=46877"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=46877"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=46877"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}